V
INFI

Veritable’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Veritable’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200,000
Closed -$420K – 835
2018
Q1 		$420K Buy
+200,000
New +$429K 0.01% 540

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Veritable's INFI Position: Q2 2018 in Review

Veritable sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2018, closing a stake of 200,000 shares — an estimated $420K sold.

Veritable first reported a position in INFI in Q1 2018 and held it in 1 quarter. The position peaked at $420K in Q1 2018. 64 funds tracked by Wall St. Rank hold INFI as of Q2 2018.

  • Veritable reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Veritable sold 200,000 Infinity Pharmaceuticals, Inc. shares in Q2 2018, an estimated $420K.
  • Veritable first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Veritable's Infinity Pharmaceuticals, Inc. position peaked at $420K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2018.

Based on Veritable's 13F filing for Q2 2018, filed 13 Aug 2018.